Christopher Raymond

Stock Analyst at Piper Sandler

(3.8)
# 2066
Out of 5,448 analysts
154
Total ratings
Success rate
Average return
42 Stocks
Name Action PT Current % Upside Ratings Updated
ARDX Ardelyx
Maintains: Neutral
8 9
6.11 47.3% 9 Aug 6, 2025
ABVX Abivax
Maintains: Overweight
42 70
74.43 -5.95% 2 Jul 23, 2025
BIIB Biogen
Maintains: Neutral
135 115
139.12 -17.34% 17 Apr 29, 2025
ALXO ALX Oncology Holding...
Maintains: Overweight
8 9
1.03 773.79% 6 Mar 6, 2025
BMRN Biomarin Pharmaceuti...
Maintains: Overweight
122 126
58.07 116.98% 12 Feb 20, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
20 4
1.88 112.77% 3 Feb 11, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
109 119
129.46 -8.08% 4 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
535 533
397.46 34.1% 8 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
1195 1013
598.45 69.27% 7 Jan 27, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
135 140
29.52 374.25% 5 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
43 30
4 650% 1 Jan 13, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
72
31.84 126.13% 1 Jan 10, 2025
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
212 220
209.42 5.05% 11 Dec 17, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
3 13
1.75 642.86% 2 Nov 18, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
60 75
6.02 1145.85% 4 Nov 6, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
66 76
14.68 417.71% 7 Sep 23, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
10 10
1.77 464.97% 2 Sep 3, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
33
11.7 182.05% 1 Aug 15, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
9 7
2.87 143.9% 2 Jul 1, 2024
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
621 35
9.81 251.68% 2 Dec 22, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
18 23
25.59 -10.12% 1 Oct 30, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
20 4
2.65 50.94% 3 Sep 19, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
22
11.77 86.92% 1 Jun 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Overweight
2 4
3.19 25.39% 3 May 31, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
25 17
16.87 0.77% 2 May 23, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
26 25
7.85 218.47% 1 May 12, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
293 288
295.76 -2.62% 11 Apr 28, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
41
38.2 7.33% 1 Feb 3, 2023
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
3 1
n/a n/a 1 Oct 13, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
6 2
n/a n/a 3 Aug 12, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
28
44.58 -37.19% 1 Jul 26, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Overweight
40 12
n/a n/a 2 May 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Maintains: Neutral
56 28
5.5 409.09% 4 May 19, 2022
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
146 180
n/a n/a 2 Sep 30, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
40
73.65 -45.69% 1 Aug 23, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Neutral
90
5.66 1490.11% 1 Jul 12, 2021
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Upgrades: Neutral
n/a
n/a n/a 3 Oct 1, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
60 35
n/a n/a 1 Aug 31, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Initiates Coverage On: Overweight
20
n/a n/a 1 Apr 9, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Downgrades: Neutral
96
1.91 4926.18% 2 Mar 13, 2020
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Overweight
170
n/a n/a 1 Oct 23, 2017
XXXX
XXXXXXXXXXXXXXXX
Upgrade
Assumes: Neutral
133
n/a n/a 2 Oct 23, 2017